Skip to main content

Advertisement

Table 1 Subject demographics percentages are based on the total number of subjects with nonmissing values in relevant treatment group

From: Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody

  SAD study MAD study
  Placebo BAN2401 (mg/kg) Placebo BAN2401 (mg/kg)
  (N = 12) 0.1 (N = 6) 0.3 (N = 6) 1 (N = 6) 3 (N = 6) 10 (N = 6) 15 (N = 6) Total (N = 36) (N = 8) 0.3 (N = 6) 1 (N = 6) 3 (N = 6) 10 (N = 6) Total (N = 24)
Age: mean year (SD) 72.1 (9.2) 70.0 (12.0) 72.7 (6.5) 75.0 (14.0) 68.2 (8.4) 68.7 (9.1) 70.8 (11.5) 70.9 (10.0) 70.0 (11.70) 69.0 (13.19) 69.0 (6.99) 71.8 (11.48) 70.3 (9.81) 70.0 (9.97)
Female gender, n (%) 5 (41.7) 4 (66.7) 2 (33.3) 2 (33.3) 3 (50.0) 2 (33.3) 5 (83.3) 18 (50.0) 2 (25.0) 2 (33.3) 5 (83.3) 4 (66.7) 2 (33.3) 13 (54.2)
MMSE (mean) 23.5 25.2 24.7 23.5 24.0 24.2 21.5 23.8 24.1 24.0 21.7 23.7 23.8 23.3
  1. MMSE Mini Mental State Examination, SAD single ascending dose, MAD multiple ascending dose